

the current level of control associated with Schedule I of the 1961 Single Convention on Narcotic Drugs for cannabis-based preparations such as Sativex and the level of control associated with Schedule II of the 1971 Convention on Psychotropic Substances, for preparations using synthetic *delta*-9 THC, *e.g.*, Marinol and Syndros.

To impede access to these medicines and in reference to Article 3.4 of the 1961 Single Convention on Narcotic Drugs:

- **Recommendation 5.6:** The Committee recommended that preparations containing *delta*-9-tetrahydrocannabinol (dronabinol), produced either by chemical synthesis or as a preparation of cannabis, that are compounded as pharmaceutical preparations with one or more other ingredients and in such a way that *delta*-9-tetrahydrocannabinol (dronabinol) cannot be recovered by readily available means or in a yield which would constitute a risk to public health, be added to Schedule III of the 1961 Convention on Narcotic Drugs.

III. Discussion

At this time, it is uncertain whether the above notification from WHO of recommendations for proposed scheduling action on cannabis and cannabis related substances will be acted upon by 62nd session of the Commission on Narcotic Drugs (from 14 to 22 March 2019). The Bureau of the 62nd Commission is currently considering whether to postpone voting on the cannabis-related recommendations until the reconvened meeting in December, or the 63rd session of the Commission on Narcotic Drugs, March 2020. If voting is deferred to a later date the comment period will be reopened.

Although WHO has made specific scheduling recommendations for each of the drug substances, the CND is not obliged to follow the WHO recommendations. Options available to the CND for substances considered for control under the 1971 Psychotropic Convention include the following: (1) Accept the WHO recommendations; (2) accept the recommendations to control but control the drug substance in a schedule other than that recommended; or (3) reject the recommendations entirely.

Cannabis, also known as marijuana, is a plant known by biological names *Cannabis sativa* or *Cannabis indica*. It is a complex plant containing multiple cannabinoids and other compounds, including the psychoactive substance THC and other structurally similar

compounds. Cannabinoids are defined as having activity at cannabinoid 1 and 2 (CB1 and CB2, respectively) receptors. Agonists of CB1 receptors are widely abused and are known to modulate motor coordination, memory processing, pain, and inflammation, and have anxiolytic effects. Marijuana is the most commonly used illicit drug in the United States.

The principal cannabinoids in the cannabis plant include THC, CBD, and cannabitol. These substances are controlled in Schedule I under the CSA. The synthetically derived single pure stereoisomer, *delta*-9-tetrahydrocannabinol (also known as dronabinol) is the active ingredient in two approved drug products in the United States, MARINOL (dronabinol) capsules, also available as a generic, and SYNDROS (dronabinol) oral solution. MARINOL is controlled in Schedule III, while SYNDROS is controlled in Schedule II under the CSA. Both MARINOL and SYNDROS are approved to treat anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional treatment.

CBD is another cannabinoid constituent of the cannabis plant. In the United States, one CBD-containing product, Epidiolex oral solution, has received marketing approval by the FDA for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years of age and older. On September 28, 2018, the Drug Enforcement Administration placed FDA-approved product Epidiolex to be marketed into Schedule V of the CSA. Currently, CBD that is not contained in an FDA-approved product with less than 0.1 percent THC is controlled as a Schedule I substance under the CSA. CBD is not specifically listed in the schedules of the 1961, 1971, or 1988 International Drug Control conventions.

FDA, on behalf of the Secretary of HHS, invites interested persons to submit comments on the notifications from the United Nations concerning these drug substances. FDA, in cooperation with the National Institute on Drug Abuse, will consider the comments on behalf of HHS in evaluating the WHO scheduling recommendations. Then, under section 201(d)(2)(B) of the CSA, HHS will recommend to the Secretary of State what position the United States should take when voting on the recommendations for control of substances under the 1971 Psychotropic

Convention at the CND meeting in March 2019.

Comments regarding the WHO recommendations for control of Cannabis and Cannabis Resin; Dronabinol (*delta*-9-tetrahydrocannabinol); Tetrahydrocannabinol (Isomers of *delta*-9-tetrahydrocannabinol); Extracts and Tinctures of cannabis; Cannabidiol Preparations; Preparations Produced Either by Chemical Synthesis or as Preparation of Cannabis; under the 1961 Single Convention will also be forwarded to the relevant Agencies for consideration in developing the U.S. position regarding narcotic substances at the CND meeting.

Dated: February 25, 2019.

Lowell J. Schiller,

Acting Associate Commissioner for Policy.

[FR Doc. 2019-03662 Filed 2-28-19; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-0671]

International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization; Scheduling Recommendations; Cyclopropyl Fentanyl; Methoxyacetyl Fentanyl; Ortho-Fluorofentanyl; Para-Fluorobutyrfentanyl; N-Ethylnorpentylone; and Four Additional Substances; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of comment.

SUMMARY: The Food and Drug Administration (FDA) is providing interested persons with the opportunity to submit written comments concerning recommendations by the World Health Organization (WHO) to impose international manufacturing and distributing restrictions, under international treaties, on certain drug substances. The comments received in response to this notice will be considered in preparing the United States' position on these proposals for a meeting of the United Nations Commission on Narcotic Drugs (CND) in Vienna, Austria, in March 18-22, 2019. This notice is issued under the Controlled Substances Act (CSA).

DATES: Submit either electronic or written comments by March 14, 2019.

The short time period for the submission of comments is needed to ensure that the Department of Health and Human Services (HHS) may, in a timely fashion, carry out the required action and be responsive to the United Nations.

ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before March 14, 2019. The <https://www.regulations.gov> electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of March 14, 2019. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

Written/Paper Submissions

Submit written/paper submissions as follows:

- **Mail/Hand delivery/Courier (for written/paper submissions):** Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and

identified, as confidential, if submitted as detailed in "Instructions."

Instructions: All submissions received must include the Docket No. FDA-2019-N-0671 for "International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; World Health Organization; Scheduling Recommendations; Cyclopropyl Fentanyl; Methoxyacetyl Fentanyl; Ortho-Fluorofentanyl; Para-Fluorobutyrfentanyl; N-Ethylnorpentylone; ADB-FUBINACA; FUB-AMB(MMB-FUBINACA_AMB-FUBINACA); ADB-CHMINACA; CUMYL-4CN-BINACA; Request for Comments." Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday.

- **Confidential Submissions—**To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <http://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the

"Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:

James R. Hunter, Center for Drug Evaluation and Research, Controlled Substance Staff, Food and Drug Administration, 10903 New Hampshire Ave. Bldg. 51, Rm. 5150, Silver Spring, MD 20993-0002, 301-796-3156, james.hunter@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

The United States is a party to the 1971 Convention on Psychotropic Substances (Psychotropic Convention). Section 201(d)(2)(B) of the CSA (21 U.S.C. 811(d)(2)(B)) provides that when the United States is notified under Article 2 of the Psychotropic Convention that the CND proposes to decide whether to add a drug or other substance to one of the schedules of the Psychotropic Convention, transfer a drug or substance from one schedule to another, or delete it from the schedules, the Secretary of State must transmit notice of such information to the Secretary of HHS. The Secretary of HHS must then publish a summary of such information in the **Federal Register** and provide opportunity for interested persons to submit comments. The Secretary of HHS must then evaluate the proposal and furnish a recommendation to the Secretary of State that shall be binding on the representative of the United States in discussions and negotiations relating to the proposal.

As detailed in the following paragraphs, the Secretary of State has received notification from the Secretary-General of the United Nations (the Secretary-General) regarding five substances to be considered for control under the Psychotropic Convention. This notification reflects the recommendation from the 41st WHO Expert Committee for Drug Dependence (ECDD), which met in November 2018. In the **Federal Register** of October 10, 2018 (83 FR 50938), FDA announced the WHO ECDD review and invited interested persons to submit information for WHO's consideration.

The full text of the notification from the Secretary-General is provided in section II of this document. Section 201(d)(2)(B) of the CSA requires the Secretary of HHS, after receiving a notification proposing scheduling, to publish a notice in the **Federal Register** to provide the opportunity for interested persons to submit information and comments on the proposed scheduling action.

The United States is also a party to the 1961 Single Convention on Narcotic Drugs (1961 Single Convention). The Secretary of State has received a notification from the Secretary-General regarding four substances to be considered for control under this convention. The CSA does not require HHS to publish a summary of such information in the **Federal Register**. Nevertheless, to provide interested and affected persons an opportunity to submit comments regarding the WHO recommendations for narcotic drugs, the notification regarding these substances is also included in this **Federal Register** notice. The comments will be shared with other relevant agencies to assist the Secretary of State in formulating the position of the United States on the control of these substances. The HHS recommendations are not binding on the representative of the United States in discussions and negotiations relating to the proposal regarding control of substances under the 1961 Single Convention.

II. United Nations Notification

The formal notification from the United Nations that identifies the drug substances and explains the basis for the recommendations is reproduced as follows (non-relevant text removed):
Reference: NAR/CL.2/2019

WHO/ECDD41; 1961C-Art.3, 1971C-Art.2 CU
2019/35/DTA/SGB (A)

The Secretary-General of the United Nations presents his compliments to the Secretary of State of the United States of America and has the honour to inform the Government that on 28 January 2019, he received a notification from the Director-General of the World Health Organization (WHO), pursuant to article 3, paragraphs 1 and 3 of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol (1961 Convention), and article 2, paragraphs 1 and 4 of the Convention on Psychotropic Substances of 1971 (1971 Convention) with the following recommendations regarding ten **New Psychoactive Substances (NPS)**:

Substances recommended to be added to Schedule I of the 1961 Convention:

—Parafluorobutyrylfentanyl

chemical name: N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide

—Ortho-fluorofentanyl

chemical name: N-(2-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide

—Methoxyacetyl fentanyl

chemical name: 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide

—Cyclopropylfentanyl

chemical name: N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide

Substances recommended to be added to Schedule II of the 1971 Convention:

—ADB-FUBINACA

chemical name: N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide

—FUB-AMB (MMB-FUBINACA, AMB-FUBINACA)

chemical name: methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate

—CUMYL-4CN-BINACA

chemical name: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide

—ADB-CHMINACA (MAB-CHMINACA)

chemical name: N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide

—N-Ethylnorpentylone (ephylone)

chemical name: 1-(2H-1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one

In the letter from the Director-General of the World Health Organization to the Secretary-General, reference is also made to the recommendation by the forty-first meeting of the WHO Expert Committee on Drug Dependence (ECDD) to keep the following New Psychoactive Substance under surveillance:

—Paramethoxybutyrylfentanyl

chemical name: N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide

In addition, in the letter from the Director-General of the World Health Organization to the Secretary-General, reference is made to the recommendations by the forty-first meeting of the WHO ECDD to keep the following two **pain-relieving medicines** under surveillance:

—Pregabalin

chemical name: (3S)-3-(aminomethyl)-5-methylhexanoic acid

—Tramadol

chemical name: (1R*,2R*)-2-[[dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol

In accordance with the provisions of article 3, paragraph 2 of the 1961 Convention and article 2, paragraph 2 of the 1971 Convention, the Secretary-General hereby transmits the notification as annex I to the present note. In connection with the notification, WHO has also submitted the relevant extract from the report of the forty-first meeting of the WHO ECDD which is hereby transmitted as annex II. For time reasons, this

notification and its annexes I and II are transmitted in English only. The notification will be transmitted in French and Spanish as soon as it becomes available.

Also in accordance with the same provisions, the notification from WHO will be brought to the attention of the sixty-second session of the Commission on Narcotic Drugs (from 14 to 22 March 2019) in document E/CN.7/2019/8 which will be made available on the website of the 62nd session of the CND: http://www.unodc.org/unodc/en/commissions/CND/session/62_Session_2019/session-62-of-the-commission-on-narcotic-drugs.html.

In order to assist the Commission in reaching a decision, it would be appreciated if the Government could communicate any comments it considers relevant to the possible scheduling of New Psychoactive Substances recommended by WHO to be placed under international control under the 1961 Convention, namely:
—Parafluorobutyrylfentanyl; Ortho-fluorofentanyl; Methoxyacetyl fentanyl; Cyclopropylfentanyl

as well as any economic, social, legal, administrative or other factors that it considers relevant to the possible scheduling of New Psychoactive Substances recommended by WHO to be placed under international control under the 1971 Convention, namely:

—ADB-FUBINACA, FUB-AMB (MMB-FUBINACA, AMB-FUBINACA), CUMYL-4CN-BINACA, ADB-CHMINACA (MAB-CHMINACA), N-Ethylnorpentylone (ephylone).

Communications should be sent to the Executive Director of the United Nations Office on Drugs and Crime, c/o Secretary, Commission on Narcotic Drugs, P.O. Box 500, 1400 Vienna, Austria, email: unodc-sgb@un.org (fax: +43-1-26060-5885), at the latest by 28 February 2019.

1 February 2019

His Excellency

Mr. Michael Pompeo

Secretary of State of the United States of America

Annex I

Letter addressed to the Secretary-General of the United Nations from the Director-General of the World Health Organization, dated 24 January 2019

“The forty-first meeting of the WHO Expert Committee on Drug Dependence (ECDD) convened from 12 to 16 November 2018 at WHO headquarters in Geneva. The objective of this meeting was to carry out an in-depth evaluation of psychoactive substances in order to determine whether the World Health

Organization (WHO) should recommend if these substances should be placed under international control or if their level of control should be changed.

The forty-first WHO ECDD reviewed ten New Psychoactive Substances (NPS), five of which are synthetic opioids and two pain-relieving medicines; pregabalin and tramadol. The ECDD scheduling recommendations for these substances are detailed below.

In addition, the forty-first WHO ECDD critically reviewed cannabis and cannabis-related substances. The recommendations regarding cannabis and cannabis-related substances are communicated to you through a separate letter under the same date as this letter.

With reference to Article 3, paragraphs 1 and 3 of the Single Convention on Narcotic Drugs (1961), as amended by the 1972 Protocol, and Article 2, paragraphs 1 and 4 of the Convention on Psychotropic Substances (1971), I am pleased to submit recommendations of the forty-first meeting of the ECDD regarding NPS and two pain-relieving medicines, tramadol and pregabalin, as follows:

New Psychoactive Substances

To be added to Schedule I of the Single Convention on Narcotic Drugs (1961):

—Parafluorobutyrylfentanyl
chemical name: N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide

—Ortho-fluorofentanyl
chemical name: N-(2-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide

—Methoxyacetyl fentanyl
chemical name: 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide

—Cyclopropylfentanyl
chemical name: N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide

To be added to Schedule II of the Convention on Psychotropic Substances (1971):

—ADB-FUBINACA

chemical name: N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide

—FUB-AMB (MMB-FUBINACA, AMB-FUBINACA)

chemical name: methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate

—CUMYL-4CN-BINACA

chemical name: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide

—ADB-CHMINACA (MAB-CHMINACA)
chemical name: N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide

—N-Ethylnorpentylone (ephylone)
chemical name: 1-(2H-1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one

To be kept under surveillance:

—Paramethoxybutyrylfentanyl
chemical name: N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide

Medicines

To be kept under surveillance:

—Pregabalin
chemical name: (3S)-3-(aminomethyl)-5-methylhexanoic acid

—Tramadol
chemical name: (1R*,2R*)-2-[(dimethylamino)methyl]-1-(3methoxyphenyl)cyclohexan-1-ol

The assessments and findings on which they are based are set out in detail in the forty-first report of the WHO Expert Committee on Drug Dependence. An extract of the report is attached in Annex II of this letter.

I am very pleased with the ongoing collaboration between WHO, the United Nations Office on Drugs and Crime (UNODC) and the International Narcotics Control Board (INCB), and in particular, how this collaboration has benefited the work of the WHO Expert Committee on Drug Dependence (including through the participation of UNODC and INCB in the forty-first meeting of the ECDD), and more generally, the implementation of the operational recommendations of the United Nations General Assembly Special Session (UNGASS) 2016.

[signed]

Annex II

Extract from the Report of the 41st Expert Committee on Drug Dependence: Fentanyl analogues, synthetic cannabinoids, cathinones, and medicines: pregabalin and tramadol

1. Fentanyl Analogues

1.1 Para-fluoro-butyrylfentanyl

Substance identification

Para-fluoro-butyrylfentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide) is a synthetic analogue of the opioid analgesic fentanyl. Samples obtained from seizures and from other collections suggest that para-fluoro-butyrylfentanyl appears in powder, tablet, nasal spray and vaping form.

WHO review history

Para-fluoro-butyrylfentanyl has not been previously pre-reviewed or

critically reviewed by the WHO Expert Committee on Drug Dependence (ECDD) [the Committee]. A direct critical review was proposed based on information brought to WHO's attention that para-fluoro-butyrylfentanyl poses serious risk to public health and has no recognised therapeutic use.

Similarity to known substances and effects on the central nervous system

Para-fluoro-butyrylfentanyl binds to μ -opioid receptors with high selectivity over κ - and δ -opioid receptors and has been shown to act as a partial agonist at the μ -opioid receptor. In animals, it produces typical opioid effects including analgesia, with a potency between that of morphine and fentanyl. In cases of non-fatal intoxication in humans, para-fluoro-butyrylfentanyl has produced signs and symptoms such as disorientation, slurred speech, unsteady gait, hypotension and pupil constriction that are consistent with an opioid mechanism of action.

Para-fluoro-butyrylfentanyl can be readily converted to its isomer *p*-fluoro-isobutyrylfentanyl (N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide), which is an opioid listed in Schedule I of the 1961 Single Convention on Narcotic Drugs.

Dependence potential

There are no studies of the dependence potential of this substance in humans or laboratory animals. However, based on its mechanism of action, para-fluoro-butyrylfentanyl would be expected to produce dependence similar to other opioid drugs.

Actual abuse and/or evidence of likelihood of abuse

There are no controlled studies of the abuse potential of para-fluoro-butyrylfentanyl and there is very little information on the extent of abuse. The substance has been detected in biological samples obtained from cases of fatal and non-fatal intoxication. Fatalities have been reported in some countries where the compound has been identified in biological fluids in combination with other drugs, including cases where death has been attributed to the effects of para-fluoro-butyrylfentanyl.

Therapeutic applications/usefulness

Para-fluoro-butyrylfentanyl is not known to have any therapeutic uses.

Recommendation

Para-fluoro-butyrylfentanyl is an opioid receptor agonist that has significant potential for dependence and

likelihood of abuse. The limited available evidence indicates that it has typical opioid adverse effects that include the potential for death due to respiratory depression. Para-fluoro-butylfentanyl has caused substantial harm and has no therapeutic usefulness. As it is liable to similar abuse and produces similar ill-effects as many other opioids placed in Schedule I of the 1961 Single Convention on Narcotic Drugs:

• **Recommendation 1.1:** The Committee recommended that Para-fluoro-butylfentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide) be added to Schedule I of the 1961 Single Convention on Narcotic Drugs.

1.2 Para-methoxy-butylfentanyl

Substance identification

Para-methoxy-butylfentanyl (N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide) is a synthetic analogue of the opioid analgesic fentanyl. Samples obtained from seizures and from other collections suggest that para-methoxy-butylfentanyl occurs in powder, tablet, and nasal spray forms.

WHO review history

Para-methoxy-butylfentanyl has not been previously pre-reviewed or critically reviewed by the WHO ECDD. A critical review was proposed based on information brought to WHO's attention that para-methoxy-butylfentanyl poses serious risk to public health and has no recognised therapeutic use.

Similarity to known substances and effects on the central nervous system

Para-methoxy-butylfentanyl binds to μ -opioid receptors with high selectivity over κ - and δ -opioid receptors and has been shown to act as a partial agonist at the μ -opioid receptor. In animals, it produces typical opioid effects, including analgesia, and in some tests it has a potency higher than morphine and close to that of fentanyl.

Reported clinical features of intoxication in which para-methoxy-butylfentanyl is involved included the typical opioid effects of reduced level of consciousness, respiratory depression and pupil constriction. In some cases, treatment with the opioid antagonist naloxone was shown to reverse the drug-induced respiratory depression. While this is consistent with an opioid mechanism of action, it should be noted that in all such cases at least one other opioid was present.

Dependence potential

There are no studies of the dependence potential of this substance in humans or laboratory animals. However, based on its mechanism of action, Para-methoxy-butylfentanyl would be expected to produce dependence similar to other opioid drugs.

Abuse potential and/or evidence of likelihood of abuse

There are no controlled studies of the abuse potential of Para-methoxy-butylfentanyl and very little information on the extent of abuse. Para-methoxy-butylfentanyl has been detected in biological samples obtained from a limited number of acute intoxication cases. Reported clinical features are consistent with opioid effects and including respiratory depression. However, in all of the documented cases of severe adverse events associated with use of para-methoxy-butylfentanyl, other fentanyl derivatives were detected and hence the role of para-methoxy-butylfentanyl is not clear.

Therapeutic applications/usefulness

Para-methoxy-butylfentanyl is not known to have any therapeutic uses.

Recommendation

The limited available information indicates that para-methoxy-butylfentanyl is an opioid drug, and an analogue of the opioid analgesic fentanyl. There is evidence of its use in a limited number of countries with few reports of intoxication and no reports of deaths. In the intoxication cases, the role of para-methoxy-butylfentanyl was not clear due to the presence of other opioids. It has no therapeutic usefulness. At this time, there is little evidence of the impact of para-methoxy-butylfentanyl in causing substantial harm that would warrant its placement under international control.

• **Recommendation 1.2:** The Committee recommended that para-methoxy-butylfentanyl (N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide) be kept under surveillance by the WHO Secretariat.

1.3 Ortho-fluorofentanyl

Substance identification

Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide) is a synthetic analogue of the opioid analgesic fentanyl. It has two positional isomers (para-fluorofentanyl and meta-fluorofentanyl).

WHO review history

Ortho-fluorofentanyl has not been previously pre-reviewed or critically reviewed by the WHO ECDD. A direct critical review was proposed based on information brought to WHO's attention that ortho-fluorofentanyl poses a serious risk to public health and has no recognised therapeutic use.

Similarity to known substances and effects on the central nervous system

Receptor binding data show that ortho-fluorofentanyl binds to μ -opioid receptors with high selectivity over κ - and δ -opioid receptors. There were no preclinical or clinical studies available in the scientific literature. However, the clinical features present in non-fatal intoxication cases include characteristic opioid effects such as loss of consciousness, pupil constriction and respiratory depression. The effects of ortho-fluorofentanyl are responsive to the administration of the opioid antagonist naloxone, further confirming its opioid agonist mechanism of action.

Dependence potential

There are no studies of the dependence potential of ortho-fluorofentanyl in humans or laboratory animals. However, based on its mechanism of action, it would be expected to produce dependence similar to other opioid drugs.

Actual abuse and/or evidence of likelihood of abuse

There are no available preclinical or clinical studies to assess the abuse liability of ortho-fluorofentanyl. There is evidence of use from several countries, including seizures in Europe and the United States. A number of confirmed fatalities associated with the compound have been reported. Ortho-fluorofentanyl is being sold as heroin or an adulterant in heroin. A number of fatalities have been associated with this substance (1 in Europe and 16 in the United States since 2016). As a consequence of ortho-fluorofentanyl cross-reacting with standard fentanyl immunoassays, it is possible that deaths due to ortho-fluorofentanyl have been attributed to fentanyl and hence the number of recorded ortho-fluorofentanyl deaths may be an underestimate. Several countries in different parts of the world have controlled ortho-fluorofentanyl.

Therapeutic applications/usefulness

Ortho-fluorofentanyl is not known to have any therapeutic uses.

Recommendation

Ortho-fluorofentanyl is an opioid receptor agonist that has potential for dependence and likelihood of abuse. The limited available evidence indicates that it has typical opioid adverse effects that include the potential for death due to respiratory depression. Ortho-fluorofentanyl has caused substantial harm and has no therapeutic usefulness. As it is liable to similar abuse and produces similar ill-effects as many other opioids placed in Schedule I of the 1961 Single Convention on Narcotic Drugs:

• **Recommendation 1.3:** The Committee recommended that ortho-fluorofentanyl (N-(2-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide) be added to Schedule I of the 1961 Single Convention on Narcotic Drugs.

1.4 Methoxyacetylfentanyl

Substance identification

Methoxyacetylfentanyl (2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide) is a synthetic analogue of the opioid fentanyl. Samples obtained from seizures and from other collections suggest that methoxyacetylfentanyl has appeared in powders, liquids, and tablets.

WHO review history

Methoxyacetylfentanyl has not been previously pre-reviewed or critically reviewed by the WHO ECDD. A critical review was proposed based on information brought to WHO's attention that methoxyacetylfentanyl poses serious risk to public health and has no recognised therapeutic use.

Similarity to known substances and effects on the central nervous system

Methoxyacetylfentanyl binds to μ -opioid receptors with high selectivity over κ - and δ -opioid receptors and has been shown to act as an agonist at the μ -opioid receptor. In animals, it produces analgesia with a potency higher than morphine and close to that of fentanyl. The analgesia was blocked by the opioid antagonist naltrexone, confirming its opioid mechanism of action.

In people using methoxyacetylfentanyl the most serious acute health risk is respiratory depression, which in overdose can lead to respiratory arrest and death. This is consistent with its opioid mechanism of action.

Dependence potential

There are no studies of the dependence potential of this substance

in humans or laboratory animals. However, based on its mechanism of action, methoxyacetylfentanyl would be expected to produce dependence similar to other opioid drugs.

Actual abuse and/or evidence of likelihood of abuse

In the animal drug discrimination model of subjective drug effects, methoxyacetylfentanyl produced effects similar to those of morphine. It also decreased activity levels and both the discriminative and rate-decreasing effects were blocked by the opioid antagonist naltrexone. Based on its receptor action and these effects in animal models, it would be expected that methoxyacetylfentanyl would be subject to abuse in a manner comparable to other opioids.

There is evidence that methoxyacetylfentanyl has been used by injection and by nasal insufflation of powder. A large number of seizures of this substance have been reported in Europe and the United States. A number of deaths have been reported in Europe and the United States in which methoxyacetylfentanyl was detected in post-mortem samples. While other drugs were present in most of these cases, methoxyacetylfentanyl was deemed the cause of death or a major contributor to death in a significant proportion of these. Several countries have controlled methoxyacetylfentanyl in their national legislation.

Therapeutic applications/usefulness

Methoxyacetylfentanyl is not known to have any therapeutic uses.

The committee considered that methoxyacetylfentanyl is a substance with high abuse liability and dependence potential. It is an opioid agonist that is more potent than morphine and its use has contributed to a large number of deaths in different regions. It has no therapeutic usefulness and it poses a significant risk to public health. The Committee considered that the evidence of its abuse warrants placement under international control.

Recommendation 1.4: The Committee recommended that methoxyacetylfentanyl (2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide) be added to Schedule I of the Single Convention on Narcotic Drugs of 1961.

1.5 Cyclopropylfentanyl

Substance identification

Cyclopropylfentanyl ((N-phenyl-N-1-(2-phenylethyl)-4-piperidyl)cyclopropanecarboxamide) is a synthetic analogue of the opioid

fentanyl. Samples obtained from seizures and from other collections suggest that cyclopropylfentanyl has appeared in powders, liquids, and tablets.

WHO review history

Cyclopropylfentanyl has not been previously pre-reviewed or critically reviewed by the WHO ECDD. A critical review was proposed based on information brought to WHO's attention that cyclopropylfentanyl poses a serious risk to public health and has no recognised therapeutic use.

Similarity to known substances and effects on the central nervous system

Cyclopropylfentanyl binds selectively to the μ opioid receptors compared to δ and κ opioid receptors. There is no further information on the actions and effects of cyclopropylfentanyl from controlled studies. Based on its role in numerous deaths, as described below, it is reasonable to consider that cyclopropylfentanyl acts as a μ opioid receptor agonist similar to morphine and fentanyl.

Dependence potential

There are no preclinical or clinical studies published in the scientific literature concerning dependence on cyclopropylfentanyl. However, based on its mechanism of action, cyclopropylfentanyl would be expected to produce dependence similar to other opioid drugs.

Actual abuse and/or evidence of likelihood of abuse

A large number of seizures of cyclopropylfentanyl have been reported from countries in different regions. In some countries, this substance has been among the most common fentanyl analogues detected in post-mortem samples. In almost all of these deaths, cyclopropylfentanyl was determined to either have caused or contributed to death, even in presence of other substances.

Therapeutic applications/usefulness

Cyclopropylfentanyl is not known to have any therapeutic uses.

Recommendation

The available evidence indicates that cyclopropylfentanyl has opioid actions and effects. It has been extensively trafficked and has been used by several different routes of administration. Its use has been associated with a large number of documented deaths, and for most of these it has been the principal cause of death. Cyclopropylfentanyl has

no known therapeutic use and has been associated with substantial harm.

• **Recommendation 1.5:** The Committee recommended that cyclopropylfentanyl (N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide) be added to Schedule I of the 1961 Single Convention on Narcotic Drugs.

2. Synthetic cannabinoids

2.1 ADB-FUBINACA

Substance identification

ADB-FUBINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide) is encountered as a powder, in solution or sprayed on herbal material that mimics the appearance of cannabis. It is sold as herbal incense or branded products with a variety of different names.

WHO review history

ADB-FUBINACA has not been previously pre-reviewed or critically reviewed by the WHO Expert Committee on Drug Dependence (ECDD). A critical review was proposed based on information brought to WHO's attention that ADB-FUBINACA poses serious risk to public health and has no recognised therapeutic use.

Similarity to known substances/effects on the central nervous system

ADB-FUBINACA is similar to other synthetic cannabinoid receptor agonists that are currently scheduled under the Convention on Psychotropic Substances of 1971. It binds to both the CB₁ and CB₂ cannabinoid receptors with full agonist activity as demonstrated by *in vitro* studies. The efficacy and potency of ADB-FUBINACA is substantially greater when compared to Δ⁹-THC. Reported clinical features of intoxication include confusion, agitation, somnolence, hypertension and tachycardia, similar to other synthetic cannabinoid receptor agonists.

Dependence potential

No controlled experimental studies examining the dependence potential of ADB-FUBINACA in humans or animals were available. However, based on its central nervous system action as a full CB₁ agonist, ADB-FUBINACA would be expected to produce dependence in a manner similar to or more pronounced than cannabis.

Actual abuse and/or evidence of likelihood of abuse

ADB-FUBINACA is sold and used as a substitute for cannabis. It is invariably smoked or vaped (*i.e.* using an e-

cigarette) but due to the nature of synthetic cannabinoid products (whereby drug components are introduced onto herbal material), users are unaware of which synthetic cannabinoid may be contained within such products. Evidence from case reports in which ADB-FUBINACA has been detected in biological samples has demonstrated that use of this substance has contributed to severe adverse reactions in humans including death. However, it was also noted that other substances, including other synthetic cannabinoids, were also present in the urine or blood following non-fatal and fatal intoxications and/or in the product used. Evidence of use has been reported in Europe, the United States and Asia. In recognition of its abuse and associated harm, ADB-FUBINACA has been placed under national control in a number of countries in several different regions.

Therapeutic applications/usefulness

There are currently no approved medical or veterinary uses of ADB-FUBINACA.

Recommendation

ADB-FUBINACA is a synthetic cannabinoid receptor agonist that is used by smoking plant material sprayed with the substance or inhaling vapour after heating. Its mode of action suggests the potential for dependence and likelihood of abuse. Its use has been associated with a range of severe adverse effects including death. These effects are similar to those produced by other synthetic cannabinoids which have a mechanism of action the same as that of ADB-FUBINACA and which are placed in Schedule II of the Convention on Psychotropic Substances of 1971. ADB-FUBINACA has no therapeutic usefulness.

• **Recommendation 2.1:** The Committee recommended that ADB-FUBINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide) be added to Schedule II of the Convention on Psychotropic Substances of 1971.

2.2 FUB-AMB

Substance identification

FUB-AMB (chemical name: methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate) is a synthetic cannabinoid that is also referred to as MMB-FUBINACA and AMB-FUBINACA. FUB-AMB is encountered as a powder, in solution or sprayed on herbal material that mimics the

appearance of cannabis. It is sold as herbal incense or branded products with a variety of different names.

WHO review history

FUB-AMB has not been previously pre-reviewed or critically reviewed by the WHO ECDD. A critical review was proposed based on information brought to WHO's attention that FUB-AMB poses serious risk to public health and has no recognised therapeutic use.

Similarity to known substances/effects on the central nervous system

FUB-AMB is similar to other synthetic cannabinoid receptor agonists that are currently scheduled under the Convention on Psychotropic Substances of 1971. It binds to both the CB₁ and CB₂ cannabinoid receptors with full agonist activity as demonstrated by *in vitro* studies. The efficacy and potency of FUB-AMB is substantially greater than Δ⁹-THC and it shares effects with other synthetic cannabinoids including severe central nervous system depression, resulting in slowed behaviour and speech.

Dependence potential

No controlled experimental studies examining the dependence potential of FUB-AMB in humans or animals were available. However, based on its central nervous system action as a full CB₁ agonist, FUB-AMB would be expected to produce dependence in a manner similar to or more pronounced than cannabis.

Actual abuse and/or evidence of likelihood of abuse

Consistent with its CB₁ cannabinoid receptor agonist activity, FUB-AMB produces complete dose-dependent substitution for the discriminative stimulus effects of Δ⁹-THC in mice by various routes of administration. This suggests that it has abuse potential at least as great as that of Δ⁹-THC.

Evidence of the use of FUB-AMB has been reported in Europe, the United States and New Zealand. It is usually smoked or vaped (*i.e.* using an e-cigarette) but due to the nature of synthetic cannabinoid products (whereby drug components are introduced onto herbal material), users are unaware of which synthetic cannabinoid may be contained within such products.

FUB-AMB use was confirmed in case reports of a mass intoxication in the United States with the predominant symptom being severe central nervous system depression, resulting in slowed behaviour and speech. It was reported that in New Zealand there were at least

20 deaths related to the use of FUB-AMB. It was noted that the amounts of FUB-AMB in confiscated products were 2 to 25 times greater than those reported in the incidents in the United States.

Therapeutic applications/usefulness

There are currently no approved medical or veterinary uses of FUB-AMB.

Recommendation

FUB-AMB is a synthetic cannabinoid receptor agonist that is used by smoking plant material sprayed with the substance or inhaling vapour after heating. Its mode of action suggests the potential for dependence and likelihood of abuse. Its use has been associated with a range of severe adverse effects including a number of deaths. Its mechanism of action and manner of use are similar to other synthetic cannabinoids placed in Schedule II of the Convention on Psychotropic Substances of 1971. FUB-AMB has no therapeutic usefulness.

• **Recommendation 2.2:** The Committee recommended that FUB-AMB (chemical name: methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate) be added to Schedule II of the Convention on Psychotropic Substances of 1971.

2.3 ADB-CHMINACA

Substance identification

ADB-CHMINACA (N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide) is a synthetic cannabinoid that is also referred to as MAB-CHMINACA. ADB-CHMINACA is encountered as a powder, in solution or sprayed on herbal material that mimics the appearance of cannabis. It is sold as herbal incense or branded products with a variety of different names.

WHO review history

ADB-CHMINACA has not been previously pre-reviewed or critically reviewed by the WHO ECDD. A critical review was proposed based on information brought to WHO's attention that ADB-CHMINACA poses a serious risk to public health and has no recognised therapeutic use.

Similarity to known substances/effects on the central nervous system

ADB-CHMINACA is similar to other synthetic cannabinoid receptor agonists that are currently scheduled under the Convention on Psychotropic Substances of 1971. It binds to both the CB₁ and CB₂ cannabinoid receptors with full agonist activity as demonstrated by *in vitro*

studies. The efficacy and potency of ADB-CHMINACA is substantially greater than Δ⁹-THC and it is among the most potent synthetic cannabinoids studied to date. It shares a profile of central nervous system mediated effects with other synthetic cannabinoids. ADB-CHMINACA demonstrates decreased locomotor activity in mice in a time and dose dependent fashion with a rapid onset of action and long-lasting effects.

Signs and symptoms of intoxication arising from use of ADB-CHMINACA have included tachycardia, unresponsiveness, agitation, combativeness, seizures, hyperemesis, slurred speech, delirium and sudden death. These are consistent with the effects of other synthetic cannabinoids.

Dependence potential

No controlled experimental studies examining the dependence potential of ADB-CHMINACA in humans or animals were available. However, based on its central nervous system action as a full CB₁ agonist, ADB-CHMINACA would be expected to produce dependence in a manner similar to or more pronounced than cannabis.

Actual abuse and/or evidence of likelihood of abuse

Consistent with its CB₁ cannabinoid receptor agonist activity, ADB-CHMINACA fully substituted for Δ⁹-THC in drug discrimination tests. This suggests that it has abuse potential at least as great as that of Δ⁹-THC.

Evidence of the use of ADB-CHMINACA has been reported in Europe, the United States and Japan, including cases of driving under the influence. It is invariably smoked or vaped (*i.e.* using an e-cigarette) but due to the nature of synthetic cannabinoid products (whereby drug components are introduced onto herbal material), users are unaware of which synthetic cannabinoid may be contained within such products.

ADB-CHMINACA use was analytically confirmed in case reports of several drug-induced clusters of severe illness and death in the United States. In Europe, 13 deaths with analytically confirmed use of ADB-CHMINACA were reported between 2014 and 2016, and another death occurred in Japan.

Therapeutic applications/usefulness

There are currently no approved medical or veterinary uses of ADB-CHMINACA.

Recommendation

ADB-CHMINACA is a synthetic cannabinoid receptor agonist that is

used by smoking plant material sprayed with the substance or inhaling vapour after heating. It has effects that are similar to other synthetic cannabinoid receptor agonists placed in Schedule II of the Convention on Psychotropic Substances of 1971. Its mode of action suggests the potential for dependence and likelihood of abuse. Its use has resulted in numerous cases of severe intoxication and death. There is evidence that ADB-CHMINACA has been associated with fatal and non-fatal intoxications in a number of countries. The substance causes substantial harm and has no therapeutic usefulness.

Recommendation 2.3: The Committee recommended that ADB-CHMINACA (chemical name: N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) be added to Schedule II of the Convention on Psychotropic Substances of 1971.

2.4 CUMYL-4CN-BINACA

Substance identification

CUMYL-4CN-BINACA (chemical name: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide) is a synthetic cannabinoid. It is encountered as a powder, in solution or sprayed on herbal material that mimics the appearance of cannabis. It is sold as herbal incense or branded products with a variety of different names.

WHO review history

CUMYL-4CN-BINACA has not been previously pre-reviewed or critically reviewed by the WHO ECDD. A critical review was proposed based on information brought to WHO's attention that CUMYL-4CN-BINACA poses serious risk to public health and has no recognised therapeutic use.

Similarity to known substances/effects on the central nervous system

CUMYL-4CN-BINACA is similar to other synthetic cannabinoid receptor agonists that are currently scheduled under the Convention on Psychotropic Substances of 1971. It binds to both the CB₁ and CB₂ cannabinoid receptors with full agonist activity as demonstrated by *in vitro* studies. The efficacy and potency of CUMYL-4CN-BINACA is substantially greater than Δ⁹-THC and it shares a profile of central nervous system mediated effects with other synthetic cannabinoids. Data have shown that it produced hypothermia in mice in common with other CB₁ cannabinoid receptor agonists.

Dependence potential

No controlled experimental studies examining the dependence potential of CUMYL-4CN-BINACA in humans or animals were available. However, based on its central nervous system action as a full CB₁ agonist, CUMYL-4CN-BINACA would be expected to produce dependence in a manner similar to or more pronounced than cannabis.

Actual abuse and/or evidence of likelihood of abuse

Consistent with its CB₁ cannabinoid receptor agonist activity, CUMYL-4CN-BINACA fully substituted for Δ⁹-THC in drug discrimination tests. This suggests that it has abuse potential at least as great as that of Δ⁹-THC.

Evidence of the use of CUMYL-4CN-BINACA has been currently reported only from Europe but this may be due to under-reporting including through lack of detection in other countries. In Europe, CUMYL-4CN-BINACA has been among the most frequently seized synthetic cannabinoids. It is invariably smoked or vaped (*i.e.* using an e-cigarette) but due to the nature of synthetic cannabinoid products (whereby drug components are introduced onto herbal material), users are unaware of which synthetic cannabinoid may be contained within such products.

A number of non-fatal intoxications involving CUMYL-4CN-BINACA have been reported. CUMYL-4CN-BINACA has been analytically confirmed as being present in 11 fatalities and 5 non-fatal intoxications in Europe. In 2 deaths, CUMYL-4CN-BINACA was the only drug present.

Therapeutic applications/usefulness

There are currently no approved medical or veterinary uses of CUMYL-4CN-BINACA.

Recommendation

CUMYL-4CN-BINACA is a synthetic cannabinoid receptor agonist that is used by smoking plant material sprayed with the substance or inhaling vapour after heating and is sold under a variety of brand names. It has effects that are similar to other synthetic cannabinoid receptor agonists placed in Schedule II of the Convention on Psychotropic Substances of 1971. Its mode of action suggests the potential for dependence and likelihood of abuse. There is evidence that CUMYL-4CN-BINACA has been associated with fatal and non-fatal intoxications in a number of countries. The substance causes substantial harm and has no therapeutic usefulness.

• **Recommendation 2.4:** The Committee recommended that CUMYL-4CN-BINACA (chemical name: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide) be added to Schedule II of the Convention on Psychotropic Substances of 1971.

3. Cathinone

3.1 N-ethylnorpentylone

Substance identification

N-Ethylnorpentylone (chemical name: 1-(2H-1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one) is a ring-substituted synthetic cathinone analogue that originally emerged in the 1960s during pharmaceutical drug development efforts. It is also known as ephylone and incorrectly referred to as N-ethylpentylone. In its pure form, N-Ethylnorpentylone exists as a racemic mixture in form of a powder or crystalline solid. However, the substance is usually available as a capsule, powered tablet, pill and powder often sold as “Ecstasy” or MDMA. N-Ethylnorpentylone is also available in its own right and is advertised for sale by internet retailers.

WHO review history

N-Ethylnorpentylone has not been previously pre-reviewed or critically reviewed by the WHO Expert Committee on Drug Dependence (ECDD). A critical review was proposed based on information brought to WHO's attention that N-Ethylnorpentylone poses serious risk to public health and has no recognised therapeutic use.

Similarity to known substances/effects on the central nervous system

The information currently available suggests that N-Ethylnorpentylone is a psychomotor stimulant. N-Ethylnorpentylone users exhibit psychomotor stimulant effects including agitation, paranoia, tachycardia and sweating which are consistent with other substituted cathinone and central nervous system stimulant drugs. Not all reported adverse effects could be causally linked to N-Ethylnorpentylone alone, but there are indications that the observed effects are consistent with those seen with other psychomotor stimulants, with some instances involving cardiac arrest.

Its molecular mechanism of action is similar to the synthetic cathinones MDPV and α-PVP which are both listed in Schedule II of the Convention on Psychotropic Substances of 1971. *In vitro* investigations showed that N-Ethylnorpentylone inhibited the reuptake of dopamine, noradrenaline and, to a lesser extent, serotonin, which

is consistent with closely related other substituted cathinones with known abuse liability and with cocaine.

There is no specific information available to indicate that N-Ethylnorpentylone may be converted into a substance currently controlled under the U.N. Conventions.

Dependence potential

No controlled experimental studies examining the dependence potential of N-Ethylnorpentylone in humans or animals were available. However, based on its action in the central nervous system, it would be expected that N-Ethylnorpentylone would have the capacity to produce a state of dependence similar to that of other stimulants such as the ones listed in Schedule II of the Convention on Psychotropic Drugs of 1971.

Actual abuse and/or evidence of likelihood of abuse

In rodent drug discrimination studies, N-Ethylnorpentylone fully substituted for methamphetamine and cocaine, and it was also shown to increase activity levels, suggesting it has potential for abuse similar to other psychomotor stimulants.

N-Ethylnorpentylone has been detected in biological fluids collected from a number of cases involving adverse effects including deaths. It is frequently used in combination with other drugs. Users may be unaware of the additional risks of harm associated with the consumption of N-Ethylnorpentylone either alone or in combination with other drugs. Users may also be unaware of the exact dose or compound being ingested.

A number of countries in various regions have reported use or detection of this compound in either seized materials or biological samples of individuals, including in cases of driving under the influence of drugs. Increased seizures of N-Ethylnorpentylone were reported by the United States over the last 2 years. N-Ethylnorpentylone has been detected in biological fluids collected from fatal and non-fatal cases of intoxication with a total of 125 toxicological reports associated with N-Ethylnorpentylone between 2016 and 2018 having been documented.

The current available data therefore suggest that N-Ethylnorpentylone is liable to abuse.

Therapeutic applications/usefulness

N-Ethylnorpentylone is not known to have any therapeutic uses.

Recommendation

N-Ethylnorpentylone is a synthetic cathinone with effects that are similar to other synthetic cathinones listed as Schedule II substances in the Convention on Psychotropic Substances of 1971. Its mode of action and effects are consistent with those of other central nervous system stimulants such as cocaine, indicating that it has significant potential for dependence and likelihood of abuse. There is evidence of use of N-Ethylnorpentylone in a number of countries in various regions and this use has resulted in fatal and non-fatal intoxications. The substance causes substantial harm and has no therapeutic usefulness. Accordingly:

• **Recommendation 3.1:** The Committee recommended that N-Ethylnorpentylone (chemical name: 1-(2H-1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one) be added to Schedule II of the 1971 Convention on Psychotropic Substances.

4. Medicines

4.1 Pregabalin

Substance identification

Chemically, pregabalin is (3S)-3-(aminomethyl)-5-methylhexanoic acid.

WHO review history

Pregabalin was reviewed by the 39th ECDD in November 2017.

Similarity to known substances/effects on the central nervous system

Pregabalin is an inhibitor of alpha-2-delta subunit containing voltage-gated calcium channels (VGCCs). Through this mechanism it decreases the release of neurotransmitters such as glutamate, noradrenaline and substance P. It has been suggested that pregabalin exerts its therapeutic effects by reducing the neuronal activation of hyper-excited neurons while leaving normal activation unaffected. The mechanism(s) by which pregabalin produces euphoric effects or induces physical dependence is unknown.

Despite being a chemical analogue of the neurotransmitter gamma aminobutyric acid (GABA), pregabalin does not influence GABA activity via either GABA receptors or benzodiazepine receptors. However, pregabalin has been found to produce effects that are similar to those produced by controlled substances, such as benzodiazepines, that increase GABA activity.

Dependence potential

Tolerance has been shown to develop to the effects of pregabalin, particularly the euphoric effects. A number of

published reports have described physical dependence associated with pregabalin use in humans. The withdrawal symptoms that occur following abrupt discontinuation of pregabalin include insomnia, nausea, headache, anxiety, sweating, and diarrhoea. Current evidence suggests that the incidence and severity of withdrawal symptoms may be dose-related and hence those taking doses above the normal therapeutic range are most at risk of withdrawal. At therapeutic doses, withdrawal may be minimized by gradual dose tapering.

Actual abuse and/or evidence of likelihood to produce abuse

While some preclinical research using self-administration and conditioned place preference models has shown reinforcing effects of pregabalin, taken as a whole, the results from such research are contradictory and inconclusive.

In clinical trials, patients have reported euphoria, although tolerance develops rapidly to this effect. Human laboratory research is very limited and only a relatively low dose of pregabalin has been tested in a general population sample; the results indicated low abuse liability. However, a higher dose of pregabalin administered to users of alcohol or sedative/hypnotic drugs was rated similar to diazepam, indicative of abuse liability.

Pregabalin is more likely to be abused by individuals who are using other psychoactive drugs (especially opioids) with significant potential of adverse effects among these subpopulations. The adverse effects of pregabalin include dizziness, blurred vision, impaired coordination, impaired attention, somnolence, confusion and impaired thinking. Other reported harms associated with non-medical use of pregabalin include suicidal ideation and impaired driving. Users of pregabalin in a number of countries have sought treatment for dependence on the drug. Whilst pregabalin has been cited as the main cause of death in over 30 documented overdose fatalities, there are very few cases of fatal intoxications resulting from pregabalin use alone and the vast majority of instances involve other central nervous system depressants such as opioids and benzodiazepines.

There is only limited information regarding the scope and magnitude of the illicit trade in pregabalin, but there is evidence of illicit marketing through online pharmacies.

Pregabalin is under national control in many countries across different regions of the world.

Therapeutic applications/usefulness

Pregabalin is used for the treatment of neuropathic pain, including painful diabetic peripheral neuropathy and postherpetic neuralgia, fibromyalgia, anxiety and the adjunctive treatment of partial seizures. The exact indications for which pregabalin has received approval vary across countries. Pregabalin has also been used for conditions such as substance use disorders, alcohol withdrawal syndrome, restless legs syndrome and migraine.

Recommendation

The Committee noted that there has been increasing concern in many countries regarding the abuse of pregabalin. A number of cases of dependence have been reported and there are increasing reports of adverse effects. While these problems are concentrated in certain drug using populations, there is presently limited data on the extent of the problems related to pregabalin abuse in the general population. The Committee also noted that pregabalin has approved therapeutic uses for a range of medical conditions, including some for which there are few therapeutic options. Given the limitations in the available information regarding the abuse of pregabalin:

• **Recommendation 4.1:** The Committee recommended that pregabalin (chemical name: (3S)-3-(aminomethyl)-5-methylhexanoic acid) should not be scheduled but be kept under surveillance by the WHO Secretariat.

4.2 Tramadol

Substance identification

Tramadol (chemical name: (1R*,2R*)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol) is a white, bitter, crystalline and odourless powder soluble in water and ethanol. Tramadol is marketed as the hydrochloride salt and is available in a variety of pharmaceutical formulations for oral (tablets, capsules), sublingual (drops), intranasal, rectal (suppositories), intravenous, subcutaneous, and intramuscular administration. It is also available in combination with acetaminophen (paracetamol). Preparations of tramadol are available as immediate- and extended-release formulations.

WHO review history

Tramadol has been considered for critical review by the ECDD five times: in 1992, 2000, 2002, 2006 and 2014. Tramadol was pre-reviewed at the 39th

ECDD meeting in November 2017 and it was recommended that tramadol be subject to a critical review at a subsequent ECDD meeting. The Committee requested the WHO Secretariat to collect additional data for the critical review, including information on the extent of problems associated with tramadol misuse in countries. Also, the Committee asked for information on the medical use of tramadol including the extent to which low income countries, and aid and relief agencies, use and possibly rely on tramadol for provision of analgesia. In response to these requests, the WHO Secretariat collected data from Member States and relief agencies on the extent of medical use of tramadol, its misuse and on the level of control implemented in countries.

Similarity to known substances/effects on the central nervous system

Tramadol is a weak opioid analgesic that produces opioid-like effects primarily due to its metabolite, O-desmethyltramadol (M1). The analgesic effect of tramadol is also believed to involve its actions on noradrenergic and serotonergic receptor systems. The adverse effects of tramadol are consistent with its dual opioid and non-opioid mechanisms of action and they include dizziness, nausea, constipation and headache. In overdose, symptoms such as lethargy, nausea, agitation, hostility, aggression, tachycardia, hypertension and other cardiac complications, renal complications, seizures, respiratory depression and coma have been reported. Serotonin syndrome (a group of symptoms associated with high concentrations of the neurotransmitter serotonin that include elevated body temperature, agitation, confusion, enhanced reflexes, and tremor and might result in seizures and respiratory arrest) is a potential complication of the use of tramadol in combination with other serotonergic drugs. Tramadol has been detected in a number of deaths. It is often present along with other drugs, including opioids, benzodiazepines and antidepressants, but fatalities have also been reported due to tramadol alone.

Dependence potential

Evidence suggests that the development of physical dependence to tramadol is dose-related, and administration of supra-therapeutic doses leads to a similar dependence profile to morphine and other opioids such as oxycodone and methadone. There are reports of considerable number of people with tramadol dependence seeking help. Withdrawal

symptoms include those typical of opioids such as pain, sweating, diarrhoea and insomnia as well as symptoms not normally seen with opioids and related to noradrenergic and serotonergic activity, such as hallucinations, paranoia, confusion and sensory abnormalities. Low dose tramadol use over extended periods is associated with a lower risk of dependence.

Actual abuse and/or evidence of likelihood of abuse

Consistent with its opioid mechanism of action, human brain imaging has shown that tramadol activates brain reward pathways associated with abuse. While reports from people administered tramadol in controlled settings have shown that it is identified as opioid-like and tramadol has reinforcing effects in experienced opioid users, these effects may be weaker than those produced by opioids such as morphine and may be partially offset by unpleasant effects of tramadol such as sweating, tremor, agitation, anxiety and insomnia.

Abuse, dependence and overdose from tramadol have emerged as serious public health concerns in countries across several regions. Epidemiological studies in the past have reported a lower tendency for tramadol misuse when compared to other opioids, but more recent information indicates a growing number of people abusing tramadol, particularly in a number of Middle Eastern and African countries. The sources of tramadol include diverted medicines as well as falsified medicines containing high doses of tramadol. Seizures of illicitly trafficked tramadol, particularly in African countries, have risen dramatically in recent years.

The oral route of administration has been the predominant mode of tramadol abuse as it results in a greater opioid effect compared to other routes. It is unlikely that tramadol will be injected to any significant extent. Abuse of tramadol is likely to be influenced by genetic factors such that some people will experience a much stronger opioid effect following tramadol administration compared to others. The genotype associated with a stronger opioid effect following tramadol administration occurs at different rates in populations across different parts of the world.

Many countries have placed tramadol under national control.

Therapeutic applications/usefulness

Tramadol is used to treat both acute and chronic pain of moderate to severe intensity. The conditions for which tramadol has been used include osteoarthritis, neuropathic pain, chronic

low back pain, cancer pain and postoperative pain. It has also been used for treatment of restless leg syndrome and opioid withdrawal management. As is the case with abuse potential, the analgesic efficacy and the nature of adverse effects experienced are strongly influenced by genetic factors. Systematic reviews have reported that the ability of tramadol to control chronic pain such as cancer pain is less than optimal, and its use is associated with a relatively high prevalence of adverse effects.

Tramadol is listed on the national essential medicines lists of many countries across diverse regions, but it is not listed on the WHO Lists of Essential Medicines.

As an opioid analgesic available in generic forms which is not under international control, tramadol is widely used in many countries where access to other opioids for the management of pain is limited. It is also used extensively by international aid organisations in emergency and crisis situations for the same reasons.

Recommendations

The Committee was concerned by the increasing evidence for tramadol abuse in a number of countries in diverse regions, in particular the widespread abuse of tramadol in many low to middle income countries. Equally concerning was the clear lack of alternative analgesics for moderate to severe pain for which tramadol is used. The Committee was strongly of the view that the extent of abuse and evidence of public health risks associated with tramadol warranted consideration of scheduling, but the Committee recommended that tramadol not be scheduled at this time in order that access to this medication not be adversely impacted, especially in countries where tramadol may be the only available opioid analgesic or in crisis situations where there is very limited or no access at all to other opioids.

The Committee also strongly urged the WHO and its partners to address, as a high priority, the grossly inadequate access and availability of opioid pain medication in low income countries. WHO and its partners are also strongly encouraged to update and disseminate WHO pain management guidelines and to support both country-specific capacity building needs and prevention and treatment initiatives in order to address the tramadol crisis in low income countries. The Committee also recommended that WHO and its partners support countries in strengthening their regulatory capacity

and mechanisms for preventing the supply and use of falsified and substandard tramadol.

Recommendation 4.2: The Committee recommended that the WHO Secretariat continues to keep tramadol under surveillance, collect information on the extent of problems associated with tramadol misuse in countries and on its medical use, and that it be considered for review at a subsequent meeting.

III. Discussion

Although WHO has made specific scheduling recommendations for each of the drug substances, the CND is not obliged to follow the WHO recommendations. Options available to the CND for substances considered for control under the Psychotropic Convention include the following: (1) Accept the WHO recommendations; (2) accept the recommendations to control, but control the drug substance in a schedule other than that recommended; or (3) reject the recommendations entirely.

ADB-FUBINACA (chemical name: *N*-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide) is an indazole-based synthetic cannabinoid that is a potent, full agonist at CB₁ receptors. This substance functionally (biologically) mimics the effects of the structurally unrelated delta-9-tetrahydrocannabinol (THC), a Schedule I substance, and the main psychoactive chemical constituent in the cannabis (marijuana) plant. Synthetic cannabinoids have been marketed under the guise of “herbal incense,” and promoted by drug traffickers as legal alternatives to marijuana. ADB-FUBINACA use has been associated with serious adverse events including death in the United States. There are no commercial or approved medical uses for ADB-FUBINACA. On April 10, 2017, ADB-FUBINACA was temporarily controlled as a Schedule I substance under the CSA. As such, additional permanent controls will be necessary to fulfill U.S. obligations if ADB-FUBINACA is controlled under Schedule II of the 1971 Convention on Psychotropic Substances.

FUB-AMB (other names: MMB-FUBINACA; AMB-FUBINACA; chemical name: methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) is an indazole-based synthetic cannabinoid that is a potent full agonist at CB₁ receptors. This substance functionally (biologically) mimics the effects of the structurally unrelated THC, a Schedule

I substance, and the main psychoactive chemical constituent in marijuana. Synthetic cannabinoids have been marketed under the guise of “herbal incense,” and promoted by drug traffickers as legal alternatives to marijuana. FUB-AMB use has been associated with serious adverse events including death in the United States. There are no commercial or approved medical uses for FUB-AMB. On November 3, 2017, FUB-AMB was temporarily controlled as a Schedule I substance under the CSA. As such, additional permanent controls will be necessary to fulfill U.S. obligations if FUB-AMB is controlled under Schedule II of the 1971 Convention on Psychotropic Substances.

ADB-CHMINACA (other name: MAB-CHMINACA; chemical name: *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indole-3-carboxamide) is an indazole-based synthetic cannabinoid that is a potent full agonist at CB₁ receptors. This substance functionally (biologically) mimics the effects of the structurally THC, a Schedule I substance, and the main psychoactive chemical constituent in marijuana. Synthetic cannabinoids have been marketed under the guise of “herbal incense,” and promoted by drug traffickers as legal alternatives to marijuana. ADB-CHMINACA use has been associated with serious adverse events including death in the United States. There are no commercial or approved medical uses for ADB-CHMINACA. On January 29, 2019, ADB-CHMINACA was permanently controlled as a Schedule I substance under the CSA. As such, additional permanent controls will not be necessary to fulfill U.S. obligations if ADB-CHMINACA is controlled under Schedule II of the 1971 Convention on Psychotropic Substances.

CUMYL-4CN-BINACA (chemical name: 1-(4-cyanobutyl)-*N*-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide) is a clandestinely produced indazole-3-carboxamide based synthetic cannabinoid that has been sold online and used to mimic the biological effects of THC, the main psychoactive chemical constituent in marijuana. Synthetic cannabinoids have been marketed under the guise of “herbal incense,” and promoted by drug traffickers as legal alternatives to marijuana. Hospital, scientific publications and law enforcement reports show that CUMYL-4CN-BUTINACA is abused for its psychoactive properties. CUMYL-4CN-BUTINACA has been associated with serious adverse events in the United States, in addition to multiple deaths in

Europe. CUMYL-4CN-BUTINACA has no commercial or medical uses. On July 10, 2018, CUMYL-4CN-BUTINACA was temporarily controlled as a Schedule I substance under the CSA. As such, additional permanent controls will be necessary to fulfill U.S. obligations if CUMYL-4CN-BUTINACA is controlled under Schedule II of the 1971 Convention on Psychotropic Substances.

Cyclopropyl fentanyl is a synthetic opioid that has a pharmacological profile similar to other Schedule I and II controlled opioid substances such as acetyl fentanyl, fentanyl, and other related μ -opioid receptor agonist substances. This clandestinely produced analog of fentanyl is associated with adverse events typically associated with opioid use such as respiratory depression, anxiety, constipation, tiredness, hallucinations, and withdrawal. Cyclopropyl fentanyl has been associated with numerous fatalities. At least 115 confirmed overdose deaths involving cyclopropyl fentanyl abuse have been reported in the United States. Cyclopropyl fentanyl has no commercial or currently accepted medical uses in the United States. On January 4, 2018, cyclopropyl fentanyl was temporarily placed into Schedule I of the CSA. As such, additional permanent controls will be necessary to fulfill U.S. obligations if Cyclopropyl fentanyl is controlled under Schedule I of the 1961 Single Convention.

Methoxyacetyl fentanyl has a pharmacological profile similar to other Schedule I and II opioid substances such as acetyl fentanyl, fentanyl, and other related μ -opioid receptor agonist substances. Evidence suggests that the pattern of abuse of fentanyl analogues, including methoxyacetyl fentanyl is similar to heroin and prescription opioid analgesics. Law enforcement and public health reports demonstrate that methoxyacetyl fentanyl is being illicitly distributed and abused. The Drug Enforcement Administration (DEA) is aware of at least two overdose deaths associated with the abuse of methoxyacetyl fentanyl in the United States. Methoxyacetyl fentanyl has no currently accepted medical use in treatment in the United States. On October 26, 2017, methoxyacetyl fentanyl was temporarily placed into Schedule I of the CSA. As such, additional permanent controls will be necessary to fulfill U.S. obligations if methoxyacetyl fentanyl is controlled under Schedule I of the 1961 Single Convention.

Para-fluorobutyrfentanyl shares pharmacological profile with other Schedule I (e.g. butyryl fentanyl) and II

(e.g., fentanyl) opioid substances. *Para*-fluorobutyrfentanyl has no currently accepted medical use in treatment in the United States. The abuse of *para*-fluorobutyrfentanyl carries public health risks similar to that of heroin, fentanyl, and prescription opioid analgesics. On February 1, 2018, *para*-fluorobutyrfentanyl was temporarily placed into Schedule I of the CSA. As such, additional permanent controls will be necessary to fulfill U.S. obligations if *Para*-fluorobutyrfentanyl is controlled under Schedule I of the 1961 Single Convention.

Ortho-fluorofentanyl has a pharmacological profile similar to fentanyl and other related μ -opioid receptor agonist. *Ortho*-fluorofentanyl has no currently accepted medical use in treatment in the United States. *Ortho*-fluorofentanyl has been encountered by law enforcement and public health officials. The DEA has received reports for at least 13 confirmed overdose deaths involving *ortho*-fluorofentanyl abuse in the United States. On October 26, 2017, *ortho*-fluorofentanyl was temporarily placed into Schedule I of the CSA. As such, additional permanent controls will be necessary to fulfill U.S. obligations if *Ortho*-fluorofentanyl is controlled under Schedule I of the 1961 Single Convention.

N-ethylnorpentylone (other name: *N*-ethylpentylone) is a synthetic cathinone with stimulant and psychoactive properties similar to cathinone, a Schedule I substance. *N*-Ethylpentylone abuse has been associated with adverse health effects leading to emergency department admissions, and deaths. *N*-Ethylpentylone has no currently accepted medical use in treatment in the United States. On August 31, 2018, *N*-ethylnorpentylone was temporarily controlled as a Schedule I substance under the CSA. As such, additional permanent controls will be necessary to fulfill U.S. obligations if *N*-ethylnorpentylone is controlled under Schedule II of the 1971 Convention on Psychotropic Substances.

FDA, on behalf of the Secretary of HHS, invites interested persons to submit comments on the notifications from the United Nations concerning these drug substances. FDA, in cooperation with the National Institute on Drug Abuse, will consider the comments on behalf of HHS in evaluating the WHO scheduling recommendations. Then, under section 201(d)(2)(B) of the CSA, HHS will recommend to the Secretary of State what position the United States should take when voting on the recommendations for control of substances under the Psychotropic

Convention at the CND meeting in March 2019.

Comments regarding the WHO recommendations for control of Cyclopropyl fentanyl; Methoxyacetyl fentanyl; *Ortho*-fluorofentanyl; *Para*-fluorobutyrfentanyl; under the 1961 Single Convention will also be forwarded to the relevant Agencies for consideration in developing the U.S. position regarding narcotic substances at the CND meeting.

Dated: February 25, 2019.

Lowell J. Schiller,

Acting Associate Commissioner for Policy.

[FR Doc. 2019-03663 Filed 2-28-19; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-0077]

Patient Perspectives on the Impact of Rare Diseases: Bridging the Commonalities; Public Meeting; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting; request for comments.

SUMMARY: The Food and Drug Administration (FDA or the Agency) is announcing a public meeting and an opportunity for public comment on “Patient Perspectives on the Impact of Rare Diseases: Bridging the Commonalities.” This public meeting is intended to obtain patients’ and caregivers’ perspectives on impacts of rare diseases on daily life and to assess commonalities that may help the Agency and medical product developers further understand and advance the development of treatments for rare diseases. Developing a treatment for a rare disease can present unique challenges, such as the small number of individuals affected and heterogenous etiologies and manifestations. While the differences between rare diseases are critically important, it is also important to assess commonalities to synergize product development in rare diseases. The goal of this meeting is to identify common issues and symptoms in rare diseases to help advance medical product development, potentially through the creation of novel endpoints or trial designs that focus on commonalities across a variety of rare diseases.

DATES: The public meeting will be held on April 29, 2019, from 1 p.m. to 5 p.m.

The online registration to attend must be received by April 15, 2019. Onsite registration on the day of the meeting will be based on space availability. Submit either electronic or written comments on the public meeting by May 30, 2019. See the **SUPPLEMENTARY INFORMATION** section for registration date and information.

ADDRESSES: The public meeting will be held at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-0002. Entrance for the public meeting participants (non-FDA employees) is through Building 1, where routine security check procedures will be performed. For parking and security information, please refer to <https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm>.

You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before May 30, 2019. The <https://www.regulations.gov> electronic filing system will accept comments until midnight Eastern Time at the end of May 30, 2019. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see “Written/Paper Submissions” and “Instructions”).